SCOPUS 정보 검색 플랫폼

Drug Information Journal

Volumn 31, Issue 3, 1997, Pages 639-646

Development of stereoisomeric (chiral) drugs: A brief review of scientific and regulatory considerations

(3) Daniels, Jonathan M a Nestmann, Earle R a Kerr, Alex b

a CanTox Inc (Canada)

b Can Tox US Inc (United States)

Author keywords

Chiral; Guidelines; Pharmaceuticals; Regulatory; Stereoisomers

Indexed keywords

ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG STRUCTURE; ENANTIOMER; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOISOMERISM; UNITED STATES;

EID: 0030800069 PISSN: 00928615 EISSN: None Source Type: Journal
DOI: 10.1177/009286159703100303 Document Type: Article

Times cited : (27)

References (10)

1
- 0027516217
- Development and registration of chiral drugs
- Witte D, Ensing K, Franke J-P, De Zeeuw R. Development and registration of chiral drugs. Pharm World Sci. 1993;15:10-16.
- (1993) Pharm World Sci. , vol.15 , pp. 10-16
- Witte, D.¹ Ensing, K.² Franke, J.-P.³ De Zeeuw, R.⁴

2
- 0029160945
- Development of chiral drugs in Japan: An update on regulatory and industrial opinion
- Shindo H, Caldwell J. Development of chiral drugs in Japan: an update on regulatory and industrial opinion. Chirality. 1995;7:349-352.
- (1995) Chirality , vol.7 , pp. 349-352
- Shindo, H.¹ Caldwell, J.²

3
- 1842301194
- Health Protection Branch Working Group on Drug Stereochemistry, Health and Welfare Canada; December
- Guidelines on the development of stereoisomeric drugs (draft). Health Protection Branch Working Group on Drug Stereochemistry, Health and Welfare Canada; December 1993.
- (1993) Guidelines on the Development of Stereoisomeric Drugs (Draft)

4
- 1842300533
- Part A. Health Protection Branch, Health and Welfare Canada
- Guidelines for conduct and analysis of bioavailability and bioequivalence studies. Part A. Health Protection Branch, Health and Welfare Canada; 1992.
- (1992) Guidelines for Conduct and Analysis of Bioavailability and Bioequivalence Studies

5
- 0003625859
- U.S. Food and Drug Administration, Center for Drugs and Biologics; February
- Guideline for submitting supporting documentation in drug applications for the manufacture of drug substances. U.S. Food and Drug Administration, Center for Drugs and Biologics; February 1987.
- (1987) Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances

6
- 0028128074
- Stereoisomeric drugs: FDA's policy statement and the impact on drug development
- Tomaszewski J, Rumore M. Stereoisomeric drugs: FDA's policy statement and the impact on drug development. Drug Devel Ind Pharm. 1994;20:119-139.
- (1994) Drug Devel Ind Pharm. , vol.20 , pp. 119-139
- Tomaszewski, J.¹ Rumore, M.²

7
- 0003671245
- U.S. Food and Drug Administration; May 1
- FDA's policy statement for the development of new stereoisomeric drugs. U.S. Food and Drug Administration; May 1, 1992.
- (1992) FDA's Policy Statement for the Development of New Stereoisomeric Drugs

8
- 0013591244
- Committee for Proprietary Medicinal Products Working Parties on Quality, Safety, and Efficacy of Medicinal Products. Note for guidance: investigation of chiral active substances, III/3501/91; 1993.
- (1993) Note for Guidance: Investigation of Chiral Active Substances, III/3501/91

9
- 0028322316
- Incoming guidelines on chirality. A challenge for pharmacokinetics in drug development
- Marzo A. Incoming guidelines on chirality. A challenge for pharmacokinetics in drug development. Arzneim Forsch. 1994;44:791-793.
- (1994) Arzneim Forsch. , vol.44 , pp. 791-793
- Marzo, A.¹

10
- 28744439512
- ICH Number S3A
- Toxicokinetics: guidance on the assessment of systemic exposure in toxicity studies. ICH Number S3A.
- Toxicokinetics: Guidance on the Assessment of Systemic Exposure in Toxicity Studies

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.